Global X Defense Tech ETF vs Zimmer Biomet Holdings Inc — how do they compare? Global X Defense Tech ETF trades at $61.96, while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc pays a 1.02% dividend while Global X Defense Tech ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| SHLD | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $104.26 |
52-Week Low | $58.20 | $79.58 |
Market Cap | — | $17.97B |
Enterprise Value | — | $25.04B |
Dividend Yield | — | 1.02% |
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $62.72, down 0.41% on the day, with a bearish technical signal overall despite oversold RSI readings. The ETF offers diversified exposure to global defense technology firms, with institutional buying interest noted in recent filings. Key support sits at $62, while resistance is at $63-$64.
Outlook is supported by rising global defense spending and geopolitical shifts, but risks include high launch costs for space-related holdings and ETF expense comparisons. The technical setup suggests potential for a near-term rebound from oversold levels, though moving averages remain bearish.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Trailing returns across standard periods
Latest headlines on both assets
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →